{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/johnson-johnson-jnj/",
 "dataUrl": "https://clearank.com/stock/johnson-johnson-jnj/data.json",
 "title": "Johnson & Johnson (JNJ) Stock Forecast & Price Target (2026)",
 "description": "Johnson & Johnson (JNJ) stock: Healthcare, Drug Manufacturers - General. $653.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Johnson & Johnson (JNJ)",
 "published": "2026-06-20T09:11:57+00:00",
 "modified": "2026-09-26T21:51:07.691+00:00",
 "generated": "2026-09-27T15:06:50.865Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "JNJ",
  "name": "Johnson & Johnson",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Drug Manufacturers - General",
  "country": "United States",
  "website": "https://www.jnj.com"
 },
 "quote": {
  "price": 271.22,
  "previousClose": 270.68,
  "change": 0.54,
  "changePercent": 0.2,
  "open": 271.70001,
  "high": 272.25,
  "low": 269.26001,
  "volume": 4085700,
  "averageVolume": 6511380,
  "marketCap": 653612697478,
  "fiftyTwoWeekHigh": 281.070007,
  "fiftyTwoWeekLow": 173.33,
  "marketOpen": false,
  "asOf": "2026-09-26T21:51:07.000Z"
 },
 "statistics": {
  "pe": 31.464037,
  "eps": 8.62,
  "dividendYield": 0.01976474040984638,
  "beta": 0.235,
  "priceToSales": 6.6743526,
  "priceToBook": 7.68677,
  "revenueTtm": 97929003008,
  "grossMargin": 0.6819043856183327,
  "returnOnEquity": 0.25742
 },
 "technicals": {
  "rsi": 38.47,
  "macd": 1.32,
  "sma50": 264.97,
  "sma200": 240.32,
  "rsiSignal": "Bearish",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 55,
  "consensus": "Hold",
  "fairValue": 282,
  "analystTarget": 282,
  "analystCount": 23,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-26T21:51:07.000Z",
  "priceAtAnalysis": 271.22,
  "volatility": {
   "daily": 1.18,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 268.51,
  "aggressiveEntry": 271.22,
  "stopLoss": 260.45,
  "stopLossPercent": 3,
  "targets": [
   276.56,
   281.93,
   289.99
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 229.82,
    "base": 292.82,
    "upside90th": 373.1
   },
   {
    "year": 2028,
    "downside10th": 224.43,
    "base": 316.15,
    "upside90th": 445.35
   },
   {
    "year": 2029,
    "downside10th": 224.35,
    "base": 341.33,
    "upside90th": 519.32
   },
   {
    "year": 2030,
    "downside10th": 227,
    "base": 368.52,
    "upside90th": 598.29
   },
   {
    "year": 2031,
    "downside10th": 231.46,
    "base": 397.88,
    "upside90th": 683.97
   },
   {
    "year": 2032,
    "downside10th": 237.3,
    "base": 429.58,
    "upside90th": 777.64
   },
   {
    "year": 2033,
    "downside10th": 244.31,
    "base": 463.79,
    "upside90th": 880.48
   },
   {
    "year": 2034,
    "downside10th": 252.35,
    "base": 500.74,
    "upside90th": 993.63
   },
   {
    "year": 2035,
    "downside10th": 261.35,
    "base": 540.63,
    "upside90th": 1118.32
   },
   {
    "year": 2036,
    "downside10th": 271.29,
    "base": 583.69,
    "upside90th": 1255.82
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "JNJ Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$271.70",
    "Day Range": "$269.26 to $272.25",
    "Prev Close": "$270.68",
    "Volume": "4.09M",
    "52-Week Range": "$173.33 to $281.07",
    "Market Cap": "$653.61B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (-1% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "JNJ Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, JNJ beat estimates 3 times. The stock rose 2 times the next day. Price tends to react positively to beats."
   ]
  },
  {
   "id": "analysis",
   "title": "JNJ Analysis",
   "text": [
    "Johnson & Johnson (JNJ) is trading above its 50-day and 200-day moving averages ($264.97 and $240.32), indicating a generally positive trend. The Relative Strength Index (RSI) at 38.47 suggests bearish momentum, implying potential for a pullback despite the upward price trend. The Moving Average Convergence Divergence (MACD) at 1.32 also points to a consolidating or slightly weakening momentum. Volume on the latest trading day was 4.09 million shares, below the average of 6.51 million, indicating subdued investor interest. Key support levels are near the 50-day SMA, while resistance may be found near recent highs. The current price action suggests a period of consolidation after recent gains, with the RSI indicating caution for further immediate upside.",
    "Insiders have sold $193.5 million worth of JNJ stock against minimal purchases, indicating a potential lack of confidence in near-term prospects.",
    "Johnson & Johnson (JNJ) has a track record of beating EPS estimates, as seen in the recent quarter ending June 2026, which provides a stable fundamental base.",
    "Analysts project revenue growth of 8.00% for the next quarter and 7.00% for the current year, suggesting an expected acceleration in top-line performance.",
    "JNJ's profit margin of 21.48% and ROE of 25.74% significantly exceed healthcare sector medians, demonstrating strong operational efficiency.",
    "Johnson & Johnson (JNJ) is expected to maintain its 'Hold' rating, with a base case price target of $282.00 for the next 6-12 months, reflecting limited upside from current levels. The company's strong profitability and consistent earnings, coupled with positive analyst sentiment and projected revenue growth, support its current valuation. However, the significant insider selling activity presents a notable risk that could cap upside potential. Should revenue growth accelerate beyond current projections or a major new drug approval emerge, the stock could surpass its fair value. Conversely, a failure to meet revenue growth expectations or increased regulatory scrutiny could lead to a downside scenario, potentially testing support levels around $240.32 (200-day SMA)."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transaction activity closely, as the current heavy selling trend may indicate management's concerns about near-term performance.",
     "Johnson & Johnson's (JNJ) RSI is in bearish territory, suggesting potential for a short-term pullback despite the stock trading above key moving averages.",
     "Consider the company's revenue growth rate relative to the sector; a sustained lag could impact long-term valuation."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold $193.5 million worth of JNJ stock against minimal purchases, indicating a potential lack of confidence in near-term prospects.",
     "source": "Insider Trading Data"
    },
    {
     "type": "Neutral",
     "title": "Consistent Earnings Performance",
     "text": "Johnson & Johnson (JNJ) has a track record of beating EPS estimates, as seen in the recent quarter ending June 2026, which provides a stable fundamental base.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Positive Forward Revenue Growth Estimates",
     "text": "Analysts project revenue growth of 8.00% for the next quarter and 7.00% for the current year, suggesting an expected acceleration in top-line performance.",
     "source": "Analyst Estimates"
    },
    {
     "type": "Neutral",
     "title": "Sector Outperformance in Profitability",
     "text": "JNJ's profit margin of 21.48% and ROE of 25.74% significantly exceed healthcare sector medians, demonstrating strong operational efficiency.",
     "source": "Company Fundamentals"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Johnson & Johnson (JNJ) exhibits strong profitability with a net profit margin of 21.48% and a return on equity of 25.74%, significantly outperforming the sector median ROE of 6.9%. The company's debt-to-equity ratio stands at 0.58, which is in line with the sector average of 0.58, indicating a manageable debt load. Valuation metrics show JNJ trading at a P/E ratio of 31.46 and a price-to-sales ratio of 6.67. While the P/E is slightly below the sector median of 31.9, the price-to-sales ratio is notably higher than the sector median of 3.7, suggesting the market is valuing JNJ's revenue stream at a premium. The company's revenue growth of 6.6% is below the sector's median of 8.1%, which, combined with the higher P/S ratio, raises questions about the sustainability of its current valuation without stronger top-line expansion.",
    "Johnson & Johnson (JNJ) most recently reported earnings for the quarter ending June 2026, beating analyst estimates with an EPS of $2.90 against an expected $2.85, resulting in a 1.75% surprise and a 1.19% stock price increase. Prior quarters show a mixed performance, including a significant EPS beat in the quarter ending December 2025 (0.38 actual vs. 0.18 estimate) but a miss in the quarter ending March 2026. The company's forward revenue growth estimates for the next quarter and year are positive, with projected growth of 8.00% and 7.00% respectively, indicating an expectation of accelerating top-line performance.",
    "The most significant risk for Johnson & Johnson (JNJ) is the heavy insider selling, with $193.5 million in dispositions against minimal purchases, signaling a potential lack of confidence from management in the near-term outlook. Additionally, the company's revenue growth of 6.6% lags the healthcare sector median of 8.1%, which could pressure future earnings and valuation multiples. The stock's price-to-sales ratio of 6.67, significantly above the sector median, also presents a valuation risk if revenue growth does not accelerate."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "653.61B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "31.46"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "8.62"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "1.95%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "281.07"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "173.33"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Bearish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($264.97) above the 200-day SMA ($240.32), price action is firmly bullish above key moving averages."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "38.47"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "1.32"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "264.97"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "240.32"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "-0.03",
    "Correlation with Nasdaq 100 (QQQ)": "-0.19",
    "Correlation with Bitcoin (BTC)": "-0.28",
    "Correlation with Gold (XAU)": "+0.10"
   }
  },
  {
   "id": "trade-plans",
   "title": "JNJ Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (38.5) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$276.56",
    "TARGET 2": "$281.93",
    "TARGET 3": "$289.99",
    "STOP LOSS": "$260.45"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+1.41%",
    "Average Feb return": "-0.31%",
    "Average Mar return": "+0.38%",
    "Average Apr return": "+1.20%",
    "Average May return": "-1.40%",
    "Average Jun return": "+2.17%",
    "Average Jul return": "+2.41%",
    "Average Aug return": "+0.89%",
    "Average Sep return": "-0.96%",
    "Average Oct return": "+0.26%",
    "Average Nov return": "+1.99%",
    "Average Dec return": "+0.47%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.18%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in JNJ in September 2016 would be worth about $23,028 today, compared with about $36,004 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in JNJ today could grow to about $21,521 by 2036 in the base case, with a bull case near $46,303 and a bear case around $10,003. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "JNJ Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $369 for JNJ by 2030 in the base case, from $271 today (1.4x over 4 years). The downside path ends near $227. These are outcomes of a Monte Carlo simulation run on JNJ's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using JNJ's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "JNJ simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$230",
        "$293",
        "$373"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$224",
        "$316",
        "$445"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$224",
        "$341",
        "$519"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$227",
        "$369",
        "$598"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$231",
        "$398",
        "$684"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$237",
        "$430",
        "$778"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$244",
        "$464",
        "$880"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$252",
        "$501",
        "$994"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$261",
        "$541",
        "$1,118"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$271",
        "$584",
        "$1,256"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "VEEV Veeva Systems Inc. NYSE $280.68 +2.12%",
     "url": "https://clearank.com/stock/veev-stock-analysis/"
    },
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $9.44 +3.06%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    },
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $38.80 +0.47%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "MRK Merck & Co., Inc. NYSE $148.78 +0.54%",
     "url": "https://clearank.com/stock/merck-mrk/"
    },
    {
     "text": "OSCR Oscar Health, Inc. NYSE $29.60 +2.53%",
     "url": "https://clearank.com/stock/oscr-stock-analysis/"
    },
    {
     "text": "GILD Gilead Sciences, Inc. NASDAQ $150.93 +0.83%",
     "url": "https://clearank.com/stock/gilead-sciences-gild/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $435.61 +2.86%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "MCK McKesson Corporation NYSE $866.64 -0.31%",
     "url": "https://clearank.com/stock/mck-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "VUG vs VOOG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vug-vs-voog/"
    },
    {
     "text": "XAG/USD vs XPT/USD Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/silver-vs-platinum/"
    },
    {
     "text": "VGT vs SMH Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vgt-vs-smh/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "JNJ Insider Trading Analysis",
   "facts": {
    "Bought": "$257.7K",
    "Sold": "$193.5M",
    "Insiders": "12",
    "Avg Transaction": "$9.2M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in JNJ",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Nov 16, 2018",
       "cells": [
        "GORSKY ALEX Chief Executive Officer",
        "Sell",
        "264.5K",
        "$38.6M"
       ]
      },
      {
       "label": "Aug 13, 2026",
       "cells": [
        "DUATO JOAQUIN BOIX Chief Executive Officer",
        "Sell",
        "123.3K",
        "$32.2M"
       ]
      },
      {
       "label": "Dec 4, 2018",
       "cells": [
        "FASOLO PETER M. PH.D. Officer",
        "Sell",
        "166.7K",
        "$24.4M"
       ]
      },
      {
       "label": "Aug 22, 2025",
       "cells": [
        "DUATO JOAQUIN BOIX Chief Executive Officer",
        "Sell",
        "125.8K",
        "$22.5M"
       ]
      },
      {
       "label": "Jan 26, 2026",
       "cells": [
        "DUATO JOAQUIN BOIX Chief Executive Officer",
        "Sell",
        "100.0K",
        "$22.1M"
       ]
      },
      {
       "label": "Feb 17, 2026",
       "cells": [
        "WOLK JOSEPH J Chief Financial Officer",
        "Sell",
        "89.7K",
        "$21.8M"
       ]
      },
      {
       "label": "Feb 15, 2018",
       "cells": [
        "STOFFELS PAULUS A Officer",
        "Sell",
        "155.3K",
        "$20.2M"
       ]
      },
      {
       "label": "Feb 17, 2026",
       "cells": [
        "SWANSON JAMES D Chief Technology Officer",
        "Sell",
        "62.1K",
        "$15.1M"
       ]
      },
      {
       "label": "Jul 24, 2017",
       "cells": [
        "STOFFELS PAULUS A Officer",
        "Sell",
        "102.7K",
        "$13.7M"
       ]
      },
      {
       "label": "Nov 22, 2022",
       "cells": [
        "TAUBERT JENNIFER L Officer",
        "Sell",
        "76.9K",
        "$13.6M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Johnson+%26+Johnson&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is Johnson & Johnson's stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Johnson & Johnson's (JNJ) stock price is projected to be $368.52 in 2030 under a base case scenario. The downside projection is $227, and the upside projection is $598.29. These figures represent statistical outcomes, not guaranteed price targets."
  },
  {
   "question": "Is Johnson & Johnson stock a buy right now?",
   "answer": "Johnson & Johnson (JNJ) is currently rated a 'Hold' with a consensus score of 55. While analysts have a 'Buy' rating and a median price target of $282.00, significant insider selling and revenue growth below the sector average suggest caution."
  },
  {
   "question": "What is Johnson & Johnson's current valuation compared to its sector?",
   "answer": "Johnson & Johnson (JNJ) trades at a P/E ratio of 31.46, slightly below the sector median of 31.9. However, its price-to-sales ratio of 6.67 is considerably higher than the sector median of 3.7, indicating a premium valuation on its revenue."
  },
  {
   "question": "How has Johnson & Johnson performed in recent earnings reports?",
   "answer": "Johnson & Johnson (JNJ) recently beat expectations for the quarter ending June 2026 with EPS of $2.90 versus an estimate of $2.85. Prior quarters have shown mixed results, including a significant beat in December 2025 but a miss in March 2026."
  },
  {
   "question": "What are the main risks facing Johnson & Johnson?",
   "answer": "Key risks for Johnson & Johnson (JNJ) include substantial insider selling, revenue growth that trails the healthcare sector average, and a high price-to-sales ratio that may not be sustainable without stronger top-line expansion."
  },
  {
   "question": "What is the outlook for Johnson & Johnson's revenue growth?",
   "answer": "Analysts project Johnson & Johnson's (JNJ) revenue to grow by 5.00% in the current quarter and 8.00% in the next quarter. For the full year, revenue growth is estimated at 7.00%, and for the next year, it is projected at 7.00%."
  },
  {
   "question": "How does Johnson & Johnson's profitability compare to its peers?",
   "answer": "Johnson & Johnson (JNJ) demonstrates strong profitability with a net profit margin of 21.48% and a return on equity of 25.74%, significantly outperforming the healthcare sector's median ROE of 6.9%."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "VEEV",
    "name": "Veeva Systems Inc. NYSE",
    "price": "$280.68",
    "change": "+2.12%",
    "url": "https://clearank.com/stock/veev-stock-analysis/"
   },
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$9.44",
    "change": "+3.06%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$38.80",
    "change": "+0.47%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "MRK",
    "name": "Merck & Co., Inc. NYSE",
    "price": "$148.78",
    "change": "+0.54%",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "OSCR",
    "name": "Oscar Health, Inc. NYSE",
    "price": "$29.60",
    "change": "+2.53%",
    "url": "https://clearank.com/stock/oscr-stock-analysis/"
   },
   {
    "ticker": "GILD",
    "name": "Gilead Sciences, Inc. NASDAQ",
    "price": "$150.93",
    "change": "+0.83%",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$435.61",
    "change": "+2.86%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "MCK",
    "name": "McKesson Corporation NYSE",
    "price": "$866.64",
    "change": "-0.31%",
    "url": "https://clearank.com/stock/mck-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "VUG vs VOOG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vug-vs-voog/"
   },
   {
    "ticker": "XAG/USD vs XPT/USD Comparison",
    "name": "",
    "url": "https://clearank.com/compare/silver-vs-platinum/"
   },
   {
    "ticker": "VGT vs SMH Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vgt-vs-smh/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   },
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   },
   {
    "ticker": "JCI",
    "text": "Johnson Controls International",
    "url": "https://clearank.com/stock/jci-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "EIGEN/USD",
    "text": "↑ 8.20%",
    "url": "https://clearank.com/crypto/eigen-usd-crypto-analysis/"
   },
   {
    "ticker": "TWLO",
    "text": "↓ 7.96%",
    "url": "https://clearank.com/stock/twlo-stock-analysis/"
   },
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "GILD",
    "text": "Gilead Sciences",
    "url": "https://clearank.com/stock/gilead-sciences-gild/"
   },
   {
    "ticker": "LLY",
    "text": "Eli Lilly",
    "url": "https://clearank.com/stock/eli-lilly-lly/"
   },
   {
    "ticker": "MRK",
    "text": "Merck",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "NVO",
    "text": "Novo Nordisk",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "PFE",
    "text": "Pfizer",
    "url": "https://clearank.com/stock/pfizer-pfe/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/06/jnj-analysis-2026-06.png",
     "url": "https://clearank.com/wp-content/uploads/2026/06/jnj-analysis-2026-06.png",
     "width": "1280",
     "height": "720",
     "caption": "Johnson & Johnson (JNJ) stock price analysis chart for June 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/johnson-johnson-jnj/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/johnson-johnson-jnj/",
        "name": "Johnson & Johnson (JNJ) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/johnson-johnson-jnj/#webpage",
     "url": "https://clearank.com/stock/johnson-johnson-jnj/",
     "name": "Johnson & Johnson (JNJ) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-06-20T09:11:57+00:00",
     "dateModified": "2026-09-26T21:51:07+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/jnj-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/johnson-johnson-jnj/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/johnson-johnson-jnj/#richSnippet",
     "headline": "Johnson & Johnson (JNJ) Stock Forecast & Price Target (2026)",
     "name": "Johnson & Johnson (JNJ) Stock Forecast & Price Target (2026)",
     "description": "Johnson & Johnson (JNJ) stock: Healthcare, Drug Manufacturers - General. $653.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-06-20T09:11:57+00:00",
     "dateModified": "2026-09-26T21:51:07+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Johnson & Johnson",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "JNJ"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardio",
      "tickerSymbol": "JNJ",
      "sameAs": "https://www.jnj.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/johnson-johnson-jnj/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/06/jnj-analysis-2026-06.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/johnson-johnson-jnj/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is Johnson & Johnson's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Johnson & Johnson's (JNJ) stock price is projected to be $368.52 in 2030 under a base case scenario. The downside projection is $227, and the upside projection is $598.29. These figures represent statistical outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is Johnson & Johnson stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Johnson & Johnson (JNJ) is currently rated a 'Hold' with a consensus score of 55. While analysts have a 'Buy' rating and a median price target of $282.00, significant insider selling and revenue growth below the sector average suggest caution."
     }
    },
    {
     "@type": "Question",
     "name": "What is Johnson & Johnson's current valuation compared to its sector?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Johnson & Johnson (JNJ) trades at a P/E ratio of 31.46, slightly below the sector median of 31.9. However, its price-to-sales ratio of 6.67 is considerably higher than the sector median of 3.7, indicating a premium valuation on its revenue."
     }
    },
    {
     "@type": "Question",
     "name": "How has Johnson & Johnson performed in recent earnings reports?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Johnson & Johnson (JNJ) recently beat expectations for the quarter ending June 2026 with EPS of $2.90 versus an estimate of $2.85. Prior quarters have shown mixed results, including a significant beat in December 2025 but a miss in March 2026."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing Johnson & Johnson?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks for Johnson & Johnson (JNJ) include substantial insider selling, revenue growth that trails the healthcare sector average, and a high price-to-sales ratio that may not be sustainable without stronger top-line expansion."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for Johnson & Johnson's revenue growth?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Analysts project Johnson & Johnson's (JNJ) revenue to grow by 5.00% in the current quarter and 8.00% in the next quarter. For the full year, revenue growth is estimated at 7.00%, and for the next year, it is projected at 7.00%."
     }
    },
    {
     "@type": "Question",
     "name": "How does Johnson & Johnson's profitability compare to its peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Johnson & Johnson (JNJ) demonstrates strong profitability with a net profit margin of 21.48% and a return on equity of 25.74%, significantly outperforming the healthcare sector's median ROE of 6.9%."
     }
    }
   ]
  }
 ]
}